In adults with heart failure with reduced ejection fraction, liraglutide was not associated with excess risk of worsening renal function versus placebo in a post hoc analysis.
In plain wordsIn adults with heart failure, liraglutide did not raise the risk of worsening kidney function compared with placebo.
- Peptide
- Liraglutide
- Outcome
- No significant changeWorsening renal function (WRF)
- Study
n = 274
- Comparator
- Placebo
- Outcome group
- Kidney function · Kidney and urinary
- Studied dose
- Dose not stated
Measurements
- Adjusted odds ratio
- 1.02 OR
- liraglutide vs placebo
Source sentences
In adjusted models, liraglutide was not associated with excess risk of WRF compared with placebo (odds ratio, 1.02 [95% CI, 0.62-1.67]).
2 context sentences(design, population, supporting numbers)
Two hundred seventy-four patients (91%) had complete data to assess for WRF defined as: increase in SCr ≥0.3 mg/dL, or ≥25% decrease in estimated glomerular filtration rate, or an increase in cystatin C ≥0.3 mg/L from baseline to 180-days.
The FIGHT (Functional Impact of GLP-1 [glucagon-like peptide-1] for Heart Failure Treatment) trial randomized 300 patients with heart failure with reduced ejection fraction (HFrEF) and a recent hospitalization for heart failure to liraglutide versus placebo.